glp-1/gip dual agonist lilly Not all weight loss treatments work the same—and choosing the right one makes all the difference. From appetite control to metabolic improvement, each option is designed with a different goal in mind 🔴Comparison of GLP-1R Mono-Agonist vs.
Description
Even in a population where weight loss is typically harder to achieve, tirzepatide outperformed every other available option
Our Clinic members lose 21% of their body weight in 12 months on average with a GLP-1 medication.* What meds are available
It shows regardless of the prior answer (yes or no), ensuring no patient is missed
Half of the participants were one or two years postpartum, while three were at least six months postpartum
People with cardiovascular disease
Of note, the finding of a markedly greater benefit on HF of efpeglenatide amongst trial participants using SGLT2 inhibitors at enrolment in the AMPLITUDE-O CVOT highlights another important point (Lam et al., 2021)
